Journey Medical (DERM) Insider Neil Herskowitz Buys 10,000 Shares
Insider Neil Herskowitz picked up 10,000 shares of Journey Medical Corporation on June 25, 2026, alongside multiple other leaders.
Reviewed by automated data checks against the source filing. How we make and check alerts
Neil Herskowitz bought 10,000 shares of Journey Medical Corporation ($DERM) on June 25, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $DERM is up 14.0% after 1 week, up 2.4% after 1 month and down 20.3% to date (from the $6.22 close on Jun 25, 2026).
DERM
Journey Medical Corporation
Key Points
- Neil Herskowitz acquired 10,000 shares of Journey Medical Corporation DERM on June 25, 2026.
- The transaction formed part of a wider group of purchases by company leaders including Toledano Miranda Jayne, Rosenwald Lindsay Md, Pearce Michael Cooper, and Smith Justin Adam on the same date.
- Shares trade around $6.62 as the firm prepares for its upcoming earnings release on November 11, 2026.
Get $DERM trade alerts by text
We text you when insiders, Congress or big funds trade $DERM. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Journey Medical Corporation alert may contain errors. Disclosures
Insider Buying and Selling at Journey Medical Corporation
Insider Neil Herskowitz added to his holdings in Journey Medical Corporation DERM by picking up 10,000 shares on June 25, 2026. This transaction arrived alongside a series of similar acquisitions filed by other corporate insiders on the exact same date. Leaders Toledano Miranda Jayne, Rosenwald Lindsay Md, Pearce Michael Cooper, and Smith Justin Adam each acquired 10,000 shares of the specialty drug developer on June 25, 2026, pointing to shared participation among the leadership group.
Stock Performance and Recent Trading Levels
Shares of Journey Medical Corporation traded near $6.62 recently, positioning the specialty pharmaceutical firm right around its 50-day moving average of $7.02 and its 200-day moving average of $6.92. The equity has moved between a 52-week low of $4.31 and a 52-week high of $9.55. With a market capitalization near $197.3 million, the company operates in a volatile sector where equity values frequently fluctuate ahead of clinical and commercial milestones.
Analysts Set New Price Targets
Analyst coverage includes a strong buy consensus rating backed by four professional opinions. On August 13, 2026, B. Riley Securities updated its outlook on the stock, maintaining a buy rating while moving its price target to $15.00 from $12.00. Across the broader professional community, target prices stretch from a low of $13.00 up to a high of $15.00, resulting in a mean target price of $13.75.
Business Focus and Operations
Journey Medical Corporation functions as a commercial-stage pharmaceutical enterprise based in Scottsdale, Arizona, focusing on developing and marketing treatments for various skin conditions in the United States. Its marketed portfolio features treatments like Qbrexza for hyperhidrosis, Accutane and Amzeeq for severe acne, and Zilxi alongside Emrosi for rosacea inflammation. The commercial lineup also covers topical solutions and barrier creams designed to heal superficial wounds and fungal infections.
Upcoming Financial Schedule
Market participants continue monitoring the calendar for the firm's next financial update. Journey Medical Corporation scheduled its upcoming earnings release for November 11, 2026, when management will report revenue figures and operational progress for the latest period.
Related Filing Alerts
Source: Neil Herskowitz's Form 4 filing on $DERM (Jun 25, 2026). Find the original filing: DERM Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts